LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023.
An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary. The call will be held at 8:30am EDT on Thursday, November 9th, 2023. Please refer to the information below for conference call dial-in information and webcast registration.
Call Details:
| Date: | Thursday, November 9th |
| Time: | 8:30am EDT |
| Domestic: | 1-877-451-6152 |
| International: | 1-201-389-0879 |
| Passcode: | 13741382 |
| CallMeTM | LINK (active 15 minutes prior to conference call) |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1635563&tp_key=28f6dfe71c |
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
| Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact John Fraunces LifeSci Advisors, LLC (917) 355-2395 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$2.10 |
| Daily Change: | -0.10 -4.55 |
| Daily Volume: | 78,185 |
| Market Cap: | US$77.910M |
January 10, 2025 January 08, 2025 December 04, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
